BioTime Inc. (BTX)

0.92
AMEX : Health Technology
Prev Close 0.99
Day Low/High 0.90 / 0.97
52 Wk Low/High 0.66 / 2.61
Avg Volume 459.10K
Exchange AMEX
Shares Outstanding 149.64M
Market Cap 148.15M
EPS -0.40
P/E Ratio 4.60
Div & Yield N.A. (N.A)
OncoCyte To Present Cancer Diagnostic Clinical Study Data At AACR Annual Meeting

OncoCyte To Present Cancer Diagnostic Clinical Study Data At AACR Annual Meeting

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that two abstracts, summarizing clinical studies of OncoCyte's PanC-Dx™ diagnostic products for bladder and breast cancer, have...

BioTime Announces Issuance Of 14 New Patents In The Fields Of Regenerative Medicine, Stem Cell Technology, And Cancer Therapy

BioTime Announces Issuance Of 14 New Patents In The Fields Of Regenerative Medicine, Stem Cell Technology, And Cancer Therapy

BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc.

BioTime Subsidiary OncoCyte Corporation Appoints William Annett To Its Board Of Directors

BioTime Subsidiary OncoCyte Corporation Appoints William Annett To Its Board Of Directors

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that William Annett has been appointed to OncoCyte's Board of Directors.

BioTime Appoints Adi Mohanty Chief Operating Officer

BioTime Appoints Adi Mohanty Chief Operating Officer

BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today announced the appointment of Adi Mohanty to the position of...

BioTime Subsidiary ES Cell International And GE Healthcare Cross-License Patents In The Field Of Cell Assays For Drug Testing

BioTime Subsidiary ES Cell International And GE Healthcare Cross-License Patents In The Field Of Cell Assays For Drug Testing

BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte.

BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment Of Clinical Study Of Urine-Based Bladder Cancer Diagnostic

BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment Of Clinical Study Of Urine-Based Bladder Cancer Diagnostic

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test.

BioTime Appoints Angus C. Russell To Board Of Directors

BioTime Appoints Angus C. Russell To Board Of Directors

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C.

BioTime To Host Investor And Analyst Day On December 15, 2014

BioTime To Host Investor And Analyst Day On December 15, 2014

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced today that it will host its Investor and Analyst Day meeting on Monday, December 15,...

Commit To Purchase BioTime At $2.50, Earn 14.5% Annualized Using Options

Commit To Purchase BioTime At $2.50, Earn 14.5% Annualized Using Options

Investors considering a purchase of BioTime, Inc. shares, but tentative about paying the going market price of $3.26/share, might benefit from considering selling puts among the alternative strategies at their disposal.

BioTime To Present At The LD Micro VII Conference

BioTime To Present At The LD Micro VII Conference

BioTime, Inc. (NYSE MKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime Reports Third Quarter Results And Recent Progress

BioTime Reports Third Quarter Results And Recent Progress

BioTime, Inc. (NYSE MKT: BTX), the leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today reported financial results for the third quarter and...

BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia™ In Europe

BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia™ In Europe

BioTime, Inc. (NYSE MKT:BTX) today reported that it has received authorization to begin its pivotal human clinical trial of Renevia™ in Europe.

BioTime, Inc. Closes $31 Million Financing

BioTime, Inc. Closes $31 Million Financing

BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it disclosed on October 3, 2014, through which BioTime received $29,425,961 and certain subsidiaries received approximately ...

Michael H. Mulroy And Stephen L. Cartt Joining BioTime Board Of Directors

Michael H. Mulroy And Stephen L. Cartt Joining BioTime Board Of Directors

BioTime, Inc. (NYSE MKT:BTX) announced today that Michael H.

BioTime, Inc. And Subsidiaries To Raise $31 Million Through Sales Of Common Shares

BioTime, Inc. And Subsidiaries To Raise $31 Million Through Sales Of Common Shares

BioTime, Inc. (NYSE MKT:BTX) today announced that it has agreed to sell up to an aggregate of 9,431,398 common shares, in a registered direct offering at an offering price of $3.

BioTime’s Subsidiary OncoCyte Corporation Announces Completion Of Multi-Site Clinical Study Of Lung Cancer Diagnostic By Collaborators At The Wistar Institute

BioTime’s Subsidiary OncoCyte Corporation Announces Completion Of Multi-Site Clinical Study Of Lung Cancer Diagnostic By Collaborators At The Wistar Institute

BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte’s collaborators at The Wistar Institute have completed enrollment of a large, multi-site study evaluating a ...

LifeMap Solutions Adds Chief Technology Officer To Leadership Team

LifeMap Solutions Adds Chief Technology Officer To Leadership Team

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary LifeMap Solutions, Inc.

Asterias Biotherapeutics Announces Distribution Date Of BioTime Warrants And Conversion Date Of Series B Common Stock Into Series A Common Stock

Asterias Biotherapeutics Announces Distribution Date Of BioTime Warrants And Conversion Date Of Series B Common Stock Into Series A Common Stock

Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that on October 1, 2014 the company will distribute 8,000,000 warrants to purchase common shares of BioTime, Inc.

BioTime, Inc.’s Subsidiary OncoCyte Corporation’s CEO Dr. Joseph Wagner To Present At BTIG’s Inaugural “Emerging Technologies In Healthcare Diagnostics” Symposium

BioTime, Inc.’s Subsidiary OncoCyte Corporation’s CEO Dr. Joseph Wagner To Present At BTIG’s Inaugural “Emerging Technologies In Healthcare Diagnostics” Symposium

OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today announced that Chief Executive Officer Joseph Wagner, Ph.

BioTime, Inc.’s Subsidiary OncoCyte Corporation And Abcodia To Collaborate On Breast Cancer Diagnostic Development

BioTime, Inc.’s Subsidiary OncoCyte Corporation And Abcodia To Collaborate On Breast Cancer Diagnostic Development

OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX), and Abcodia Ltd.

BioTime Subsidiary, Asterias Biotherapeutics, And Cancer Research UK And Cancer Research Technology Partner For Clinical Trial Of Immunotherapy Vaccine For Lung Cancer

BioTime Subsidiary, Asterias Biotherapeutics, And Cancer Research UK And Cancer Research Technology Partner For Clinical Trial Of Immunotherapy Vaccine For Lung Cancer

BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias Biotherapeutics, Inc.

BioTime CEO Dr. Michael D. West To Present At Rodman & Renshaw 16th Annual Healthcare Conference

BioTime CEO Dr. Michael D. West To Present At Rodman & Renshaw 16th Annual Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime To Collaborate With The University Of Wisconsin And Louvain University In Test Of HyStem®-Based Hydrogel For Vocal Fold Scarring

BioTime To Collaborate With The University Of Wisconsin And Louvain University In Test Of HyStem®-Based Hydrogel For Vocal Fold Scarring

BioTime, Inc. (NYSE MKT:BTX) today announced that it has entered into a collaboration with Susan Thibeault, Ph.

BioTime Receives FDA Premarket Notification Clearance For Premvia™ 510(k)

BioTime Receives FDA Premarket Notification Clearance For Premvia™ 510(k)

BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA’s Center for Devices and Radiologic Health that Premvia™ has been cleared for marketing as a Class II medical device.

BioTime Announces Second Quarter 2014 Results And Recent Developments

BioTime Announces Second Quarter 2014 Results And Recent Developments

BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the first quarter ended June 30, 2014 and highlighted recent corporate accomplishments.

BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development Of Bladder Cancer Diagnostic By Initiating A Large Multi-Site Clinical Trial

BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development Of Bladder Cancer Diagnostic By Initiating A Large Multi-Site Clinical Trial

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site...